Overview

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance pemetrexed or placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Pemetrexed